US equities
|
MU
$1,067.50
▼-1.88%
NVDA
$236.09
▼-0.58%
PLTR
$199.65
▲+2.85%
SNDK
$1,640.63
▼-3.06%
AMD
$636.45
▼-1.46%
INTC
$109.65
▼-3.06%
META
$721.32
▲+0.00%
SPCX
$164.48
▼-1.86%
MU
$1,067.50
▼-1.88%
NVDA
$236.09
▼-0.58%
PLTR
$199.65
▲+2.85%
SNDK
$1,640.63
▼-3.06%
AMD
$636.45
▼-1.46%
INTC
$109.65
▼-3.06%
META
$721.32
▲+0.00%
SPCX
$164.48
▼-1.86%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Betterlife Pharma Inc
(CSE:
BETR
)
0.2600
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Betterlife Pharma Inc
< Previous
1
2
Next >
Better Home & Finance Announces Closing of Business Combination
August 23, 2023
From
Better Home & Finance
Via
Business Wire
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
July 13, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
June 27, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
June 08, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
June 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
April 25, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
March 22, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
March 29, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
January 26, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
March 09, 2023
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife Announces Closing of Private Placement
December 07, 2022
From
BetterLife Pharma Inc.
Via
GlobeNewswire
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
December 02, 2022
From
BetterLife Pharma Inc.
Via
GlobeNewswire
EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!
↗
November 15, 2021
Image Provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
< Previous
1
2
Next >
